|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Table A22–1 Health Care Costs Associated with Rotavirus Infection
that 15% of infants and children receive medical attention. It is further assumed that a small percentage of children with rotavirus infection are hospitalized. VACCINE DEVELOPMENTThe committee assumed that it would take 3 years until licensure of a rotavirus vaccine and that $120 million needed to be invested. During the time the committee report was in final stages of analysis and preparation, the rotavirus vaccine was approved for licensure. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report. VACCINE PROGRAM CONSIDERATIONSTarget PopulationFor the purposes of the calculations in this report, it is assumed that the target population for this vaccine is the annual birth cohort of infants. It was assumed that 90% of the target population would utilize the vaccine. Vaccine Schedule, Efficacy, and CostsFor the purposes of the calculations in this report, it was estimated that this vaccine would cost $50 per dose and that administration costs would be $10 per dose. Default assumptions of a 3-dose series and 75% effectiveness were accepted. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report. RESULTSIf a vaccine program for rotavirus were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annu-
|
|
|||||||||||||||||||||||||||||||||||
